Why is Colinz Labs falling/rising?

As of 27-Jun, Colinz Laboratories Ltd is experiencing a decline in its stock price, currently at 45.36, which represents a decrease of 0.92 or 1.99%. The stock has been underperforming significantly, with a consecutive fall over the last 18 days resulting in a total decline of 30.38%. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Despite a rise in delivery volume by 56.52% against the 5-day average, the company faces weak long-term fundamentals, including a negative CAGR growth in net sales over the last five years and a poor EBIT to interest ratio of 0.36. The stock's return on equity is low at 4.40%, indicating low profitability, and it has an expensive valuation with a price to book value of 2.2.
In the broader market context, Colinz Laboratories Ltd has underperformed compared to the Sensex, which has gained 2.00% over the past week while the stock has dropped 9.57%. Over the past month, the stock has decreased by 27.77%, contrasting with the Sensex's increase of 3.07%. This stark difference highlights the stock's struggles relative to the overall market performance, further compounded by the company's flat results and low profitability metrics. While the stock generated an 8.08% return over the past year, its profits have only risen by 1%, leading to a high PEG ratio of 10.2, which suggests that the stock may be overvalued compared to its growth prospects.